ClinicalTrials.gg
RecruitingNCT07935681FEASIUpdated Nov 13, 2026

Foley Catheter vs. Foley + Extra-amniotic Saline Infusion for Labor Induction at 41 Weeks and Beyond

An interventional study of Foley Catheter with Extra-amniotic Saline Infusion (EASI) and Foley Catheter Alone in Labor Induction, Post-term Pregnancy and Cervical Ripening, sponsored by Ankara City Hospital Bilkent. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Ankara City Hospital Bilkent · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Feb 2026, registered Nov 2026).
  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This study is a prospective, randomized controlled trial conducted at Ankara Bilkent City Hospital to compare two mechanical methods for labor induction in post-term pregnancies. The research evaluates the efficacy and safety of a Foley catheter alone versus a Foley catheter combined with extra-amniotic saline infusion (EASI). The study specifically targets primiparous women with a gestational age greater than or equal to 41+0 weeks and an unfavorable cervix, defined as an initial Bishop score less than or equal to 6. The primary objective is to determine the change in the Bishop score within the first 6 hours to identify which method more effectively promotes cervical ripening and successful labor induction.

Read the detailed description

Background and Rationale: Labor induction is the artificial initiation of contractions before spontaneous labor to achieve vaginal delivery. Mechanical methods, such as the Foley catheter, induce cervical ripening by creating physical pressure and stimulating the local release of prostaglandins. This study aims to provide evidence-based data on whether the addition of a continuous saline infusion (EASI) to the Foley catheter results in shorter labor durations and higher vaginal delivery rates compared to the catheter alone.

Study Design and Population:

  • Design: A prospective, 1:1 randomized controlled clinical trial.
  • Setting: All procedures are conducted under standardized aseptic conditions by trained operators in the delivery unit of Ankara Bilkent City Hospital.
  • Sample Size: Based on a power analysis with an effect size of $d = 0.80$, a total of 60 to 64 participants (30 to 32 per group) will be enrolled to account for potential data loss.

Inclusion and Exclusion Criteria:

  • Inclusion: Primiparous women , gestational age greater than or equal to 41+0 weeks , singleton pregnancy in cephalic presentation , reactive non-stress test (NST) with a biophysical profile greater than or equal to 8/10 , and a Bishop score less than or equal to 6.
  • Exclusion: Multiple pregnancies , ruptured membranes , previous uterine surgery (e.g., Cesarean section) , placenta previa , fetal growth restriction (IUGR) , or high-risk systemic diseases such as severe heart disease or diabetes.

Study Procedures and Monitoring: Participants are randomly assigned to either the Foley group or the Foley+EASI group. Labor progress is monitored according to standard obstetric protocols. The study monitors several parameters, including the time from induction to active labor, total delivery time, and the mode of delivery.

Outcome Measures:

  • Primary Outcome: Change in the Bishop score recorded 6 hours after induction.
  • Secondary Outcomes: Vaginal delivery rate within 24 hours , Cesarean section rates and indications , maternal infection indicators such as fever greater than or equal to 38°C or chorioamnionitis , and neonatal outcomes including Apgar scores and birth weight.

Statistical Analysis: Data will be analyzed using descriptive statistics. Continuous variables will be compared using the Student's t-test or Mann-Whitney U test , while categorical variables will be evaluated using the Chi-square or Fisher's exact test. A p-value less than 0.05 will be considered statistically significant.

02

Conditions studied

  • Labor Induction
  • Post-term Pregnancy
  • Cervical Ripening
  • Nulliparity

Browse trials for

Keywords

  • Foley Catheter
  • Extra-amniotic Saline Infusion (EASI)
  • Bishop Score
  • Mechanical Induction of Labor
  • Randomized Controlled Trial
  • Primiparous Women
  • Vaginal Delivery
03

In context

Pregnancy, Prolonged

30 studies on the registry are indexed under Pregnancy, Prolonged; 3 are open to participants now.

This study's planned enrollment of 64 is below the median of 128 across 24 interventional studies indexed under Pregnancy, Prolonged.

Browse Pregnancy, Prolonged studies →

Lead sponsor

Ankara City Hospital Bilkent is the lead sponsor of 445 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Primiparous women (First-time mothers).

Gestational age greater than or equal to 41+0 weeks.

Singleton pregnancy in cephalic presentation.

Unfavorable cervix, defined as a Bishop score less than or equal to 6.

Reactive Non-Stress Test (NST) and a biophysical profile score greater than or equal to 8/10.

Aged greater than or equal to 18 years.

Willingness to provide written . -

Exclusion criteria

Exclusion Criteria:

Multiple pregnancies (e.g., twins, triplets).

Previous uterine surgery (e.g., prior Cesarean section or myomectomy).

Premature Rupture of Membranes (PROM).

Presence of placenta previa or vasa previa.

Fetal growth restriction (IUGR).

Active genital herpes infection.

Known to the materials used (e.g., latex allergy if applicable).

Serious maternal systemic diseases (e.g., severe heart disease, uncontrolled diabetes, or preeclampsia).

Fetal anomalies or non-reassuring fetal heart rate patterns.

-

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Foley Catheter + EASI

    "Participants in this arm will receive a single-balloon Foley catheter (16-18 French) inserted into the extra-amniotic space through the internal os of the cervix. The balloon will be inflated with 30-50 ml of sterile saline. Additionally, a continuous extra-amniotic saline infusion (EASI) will be administered at a rate of 30 ml/hour to enhance cervical ripening."

    Procedure: Foley Catheter with Extra-amniotic Saline Infusion (EASI)

  • Active comparator
    Foley Catheter Alone

    Participants in this arm will receive a single-balloon Foley catheter (16-18 French) inserted into the extra-amniotic space through the internal os of the cervix. The balloon will be inflated with 30-50 ml of sterile saline. No additional saline infusion will be administered. This group serves as the standard mechanical induction control."

    Procedure: Foley Catheter Alone

Interventions

  • ProcedureFoley Catheter with Extra-amniotic Saline Infusion (EASI)

    A single-balloon Foley catheter (16-18 French) is inserted through the internal os of the cervix into the extra-amniotic space under aseptic conditions. The balloon is inflated with 30-50 ml of sterile saline. Following placement, a continuous extra-amniotic saline infusion (EASI) is administered through the catheter at a constant rate of 30 ml per hour using an infusion pump. The procedure aims to induce cervical ripening through both mechanical pressure and biochemical stimulation.

    Also known as: Extra-amniotic Saline Infusion, EASI with Foley Catheter, Combined Mechanical Induction, Transcervical Saline Infusion

  • ProcedureFoley Catheter Alone

    A single-balloon Foley catheter (16-18 French) is inserted through the internal os of the cervix into the extra-amniotic space under aseptic conditions. The balloon is inflated with 30-50 ml of sterile saline. The catheter is then taped to the inner thigh of the patient to maintain tension. No saline infusion is administered in this group. The catheter remains in place until spontaneous expulsion or for a maximum duration of 12 hours.

    Also known as: Transcervical Foley Catheter, Intrauterine Foley Balloon, Mechanical Cervical Ripening, Single-balloon Foley Catheter

06

What researchers measure

Primary outcomes

  1. Change in Bishop Score (ΔBishop)

    The Bishop score is a pre-labor scoring system to assist in predicting whether induction of labor will be required. The score (ranging from 0 to 13) evaluates cervical dilation, effacement, consistency, position, and fetal station. This measure represents the numerical increase in the score after 6 hours of induction.

    Time frame: From baseline (0 hour) to 6 hours after catheter insertion

Secondary outcomes

  1. Rate of Vaginal Delivery within 24 Hours

    The percentage of participants who achieved a successful vaginal delivery within the first 24 hours

    Time frame: Within 24 hours of induction initiation

  2. Total Induction to Delivery Duration

    The total time elapsed (in hours) from the beginning of the induction procedure to the actual delivery

    Time frame: From the start of catheter insertion until the birth of the neonate (typically up to 48 hours).

  3. Neonatal Apgar Scores

    Evaluation of the newborn's physical condition using the Apgar scoring system (0-10 scale).

    Time frame: At 1 minute and 5 minutes after birth.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Abramovici D, Goldwasser S, Mabie BC, Mercer BM, Goldwasser R, Sibai BM. A randomized comparison of oral misoprostol versus Foley catheter and oxytocin for induction of labor at term. Am J Obstet Gynecol. 1999 Nov;181(5 Pt 1):1108-12. doi: 10.1016/s0002-9378(99)70090-6. PubMed 10561627 ↗
  • Karjane NW, Brock EL, Walsh SW. Induction of labor using a foley balloon, with and without extra-amniotic saline infusion. Obstet Gynecol. 2006 Feb;107(2 Pt 1):234-9. doi: 10.1097/01.AOG.0000198629.44186.c8. PubMed 16449106 ↗
  • Vaknin Z, Kurzweil Y, Sherman D. Foley catheter balloon vs locally applied prostaglandins for cervical ripening and labor induction: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010 Nov;203(5):418-29. doi: 10.1016/j.ajog.2010.04.038. PubMed 20605133 ↗

Individual participant data

Plan to share: No — There is no plan to share individual participant data. The study results will be published in aggregate form in a peer-reviewed journal

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 13, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Jan 10, 2027
CompletionEst.
Feb 10, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07935681
Responsible party
Ayşenur Türe (Specialist, Ankara City Hospital Bilkent) — Principal investigator
First posted
Nov 13, 2026
Start date
Feb 1, 2026
Primary completion
Jan 10, 2027 (estimated)
Completion
Feb 10, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

AYŞENUR TÜRE, M.D
Contact
draysenuryeniceri@gmail.com
+905377871445

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion